Document:

EX-10.9

 Exhibit 10.9 

FORWARD PURCHASE AGREEMENT 

This Forward Purchase Agreement (this “Agreement”) is entered into as of
                , 2021, by and among Sound Point Acquisition Corp I, Ltd, a Cayman Islands exempted company (the “Company”), and the party listed as the
purchaser on the signature page hereof (the “Purchaser”). 
 WHEREAS, the Company was incorporated for the purpose of
effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a “Business Combination”); 

WHEREAS, the Company has filed with the U.S. Securities and Exchange Commission (the “SEC”) a Registration Statement on Form S-1 (File No. 333-[•]) (the “Registration Statement”) for its initial public offering (“IPO”) of units (the “Units”) at a price of $10.00 per Unit, where
each Unit is comprised of one Class A ordinary share of the Company, par value $0.0001 per share (the “Class A ordinary shares”), and one-third of one redeemable
warrant, where each whole redeemable warrant is exercisable to purchase one Class A ordinary share at an exercise price of $11.50 per share (each such whole redeemable warrant, a “Warrant”); 

WHEREAS, following the closing of the IPO (the “IPO Closing”), the Company will seek to identify and consummate a Business
Combination; and 
 WHEREAS, the parties wish to enter into this Agreement, pursuant to which concurrently with the closing of the
Company’s initial Business Combination (the “Business Combination Closing”), the Company may issue and sell, and the Purchaser may purchase, on a private placement basis, an aggregate of up to such number of Class A
ordinary shares with an aggregate value of $50,000,000 as determined herein (the “Forward Purchase Shares”) and on the terms and conditions set forth herein. 

NOW, THEREFORE, in consideration of the premises, representations, warranties and the mutual covenants contained in this Agreement, and for
other good and valuable consideration, the receipt, sufficiency and adequacy of which are hereby acknowledged, the parties hereto agree as follows: 
  

	 	1.	 SALE AND PURCHASE. 

(a) Forward Purchase Shares. 

(i) Subject to the terms and conditions set forth in this Agreement, the Company shall issue and sell to the Purchaser, and the
Purchaser shall purchase from the Company, up to 5,000,000 Forward Purchase Shares, at a purchase price of $10.00 per Forward Purchase Share, or an aggregate purchase price of up to $50,000,000 (the “FPS Purchase Price”). 

 (ii) The Company shall have the option, exercisable in its sole discretion,
to request that the Purchaser purchase the Forward Purchase Shares pursuant to Section 1(a)(i) hereof by delivering written notice of such election (the “Company Election Notice”) to the Purchaser, at least
ten (10) Business Days before the funding of the FPS Purchase Price to an account specified by the Company. The Company Election Notice shall specify the anticipated date of the Business Combination Closing, the number of the Forward Purchase
Shares it is requesting that the Purchaser purchase, the aggregate FPS Purchase Price and instructions for wiring the FPS Purchase Price to an account designated by the Company. Subject to the Purchaser first receiving internal investment committee
approval to purchase such Forward Purchase Shares, the Purchaser shall thereafter purchase such Forward Purchase Shares on the terms set forth in this Section 1(a)(ii). Except in the event that Purchaser has not received
internal investment committee approval to purchase such Forward Purchase Shares prior to the Company entering into a definitive agreement for the initial Business Combination (the “Purchase Deadline”), the Purchaser shall deliver
the FPS Purchase Price in cash via wire transfer to the account specified in such written notice on or before the Purchase Deadline, to be held in escrow pending the Business Combination Closing. If the Business Combination Closing does not occur
within thirty (30) days after the Purchaser delivers the FPS Purchase Price to such account, the Company shall return to the Purchaser the FPS Purchase Price; provided that the return of the FPS Purchase Price placed in escrow shall not
terminate this Agreement or otherwise relieve either party of any of its obligations hereunder. The Purchaser agrees that it shall cooperate in good faith and use reasonable best efforts to effect the funding of the FPS Purchase Price on such notice
as necessary to facilitate the consummation of the proposed Business Combination, except in the event that Purchaser has not received internal investment committee approval to purchase such Forward Purchase Shares on or before the Purchase Deadline,
in which case it shall be under no such obligation. For the purposes of this Agreement, “Business Day” means any day, other than a Saturday or a Sunday, that is neither a legal holiday nor a day on which banking institutions are
generally authorized or required by law or regulation to close in the City of New York, New York. 
 (iii) The Purchaser
shall have the option, exercisable in its sole discretion, to request that the Company issue and sell to the Purchaser the Forward Purchase Shares pursuant to Section 1(a)(i) hereof by delivering written notice (the
“Purchaser Election Notice”) at least fifteen (15) Business Days before the funding of the FPS Purchase Price to an account specified by the Company. The Purchaser Election Notice shall specify the anticipated date of the
Business Combination Closing, the number of the Forward Purchase Shares it is requesting that the Company issue and sell and the aggregate FPS Purchase Price for such Forward Purchase Shares. Subject to the Company first receiving approval of the
Company’s board of directors to issue and sell such Forward Purchase Shares, the Company shall thereafter issue and sell such Forward Purchase Shares on the terms set forth in this Section 1.(a)(iii). Except in the
event that the Company has not received approval of the Company’s board of directors to issue and sell such Forward Purchase Shares two (2) Business Days before the anticipated date of the Business Combination Closing specified in such
written notice (the “Sale Deadline”), the Purchaser shall deliver the FPS Purchase Price in cash via wire transfer to an account specified by the Company on or before the Sale Deadline, to be held in escrow pending the Business
Combination 

  
 2 

 
Closing. If the Business Combination Closing does not occur within thirty (30) days after the Purchaser delivers the FPS Purchase Price to such account, the Company shall return to the
Purchaser the FPS Purchase Price; provided that the return of the FPS Purchase Price placed in escrow shall not terminate this Agreement or otherwise relieve either party of any of its obligations hereunder. The Company agrees that it shall
cooperate in good faith and use reasonable best efforts to effect the funding of the FPS Purchase Price on such notice as necessary to facilitate the consummation of the proposed Business Combination, except in the event that the Company has not
received internal board approval to issue and sell such Forward Purchase Shares on or before the Sale Deadline, in which case it shall be under no such obligation. 

(iv) A closing of the sale of the Forward Purchase Shares (the “FPS Closing”) shall be held on the same date
as, and immediately prior to, the Business Combination Closing (such date being referred to as the “Closing Date”). At the FPS Closing, the Company will issue to the Purchaser the Forward Purchase Shares each registered in the name
of the Purchaser. 
 (b) Delivery of Forward Purchase Shares. 

(i) The Company shall register the Purchaser as the owner of the Forward Purchase Shares purchased by the Purchaser hereunder
with the Company’s transfer agent by book entry on or promptly after (but in no event more than two (2) Business Days after) the Closing Date. 

(ii) Each book entry for the Forward Purchase Shares purchased by the Purchaser hereunder shall contain a notation, and each
certificate (if any) evidencing the Forward Purchase Shares shall be stamped or otherwise imprinted with a legend, in substantially the following form: 

“THE OFFER AND SALE OF THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, OR
THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE TRANSFERRED IN VIOLATION OF SUCH ACT AND LAWS.” 
 (c)
Legend Removal. If the Forward Purchase Shares are eligible to be sold without restriction under Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”), then at the Purchaser’s request, the Company
will, at its sole expense, cause the Company’s transfer agent to remove the legend set forth in Section 1(b)(ii) hereof with respect to such Forward Purchase Shares that the Purchaser intends to sell in accordance with Rule 144. In
connection therewith, if required by the Company’s transfer agent, the Company will promptly cause an opinion of counsel to be delivered to and maintained with its transfer agent, together with any other authorizations, certificates and
directions required by the transfer agent, that authorize and direct the transfer agent to transfer such Forward Purchase Shares without any such legend; provided, however, that the Company shall not be required to deliver any such
opinion, authorization or certificate or direction if it reasonably believes that removal of the legend could reasonably be expected to result in or facilitate transfers of Forward Purchase Shares in violation of applicable law. 

  
 3 

 (d) Registration Rights. The Purchaser shall have registration rights with respect to
the Forward Purchase Shares as set forth on Exhibit A (the “Registration Rights”). 
 2. REPRESENTATIONS AND
WARRANTIES OF THE PURCHASER. The Purchaser represents and warrants to the Company as follows, as of the date hereof: 
 (a)
Organization and Power. The Purchaser is duly organized, validly existing, and in good standing under the laws of the jurisdiction of its formation (if the concept of “good standing” is a recognized concept in such jurisdiction) and
has all requisite power and authority to carry on its business as presently conducted and as proposed to be conducted. 
 (b)
Authorization. The Purchaser has full power and authority to enter into this Agreement. This Agreement, when executed and delivered by the Purchaser, will constitute the valid and legally binding obligation of the Purchaser, enforceable in
accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting enforcement of creditors’ rights generally,
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies, or (iii) to the extent the indemnification provisions contained in the Registration Rights may be limited by
applicable federal or state securities laws. 
 (c) Governmental Consents and Filings. No consent, approval, order or authorization
of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the part of the Purchaser in connection with the consummation of the transactions contemplated by this
Agreement. 
 (d) Compliance with Other Instruments. The execution, delivery and performance by the Purchaser of this Agreement and
the consummation by the Purchaser of the transactions contemplated by this Agreement will not result in any violation or default (i) of any provisions of its organizational documents, if applicable, (ii) of any instrument, judgment, order,
writ or decree to which it is a party or by which it is bound, (iii) under any note, indenture or mortgage to which it is a party or by which it is bound, (iv) under any lease, agreement, contract or purchase order to which it is a party
or by which it is bound or (v) of any provision of federal or state statute, rule or regulation applicable to the Purchaser, in each case (other than clause (i)), which would have a material adverse effect on the Purchaser or its ability to
consummate the transactions contemplated by this Agreement. 
 (e) Purchase Entirely for Own Account. This Agreement is made with the
Purchaser in reliance upon the Purchaser’s representation to the Company, which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Forward Purchase Shares to be acquired by the Purchaser will be
acquired for investment for the Purchaser’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Purchaser has no present intention of selling, granting any participation
in, or otherwise distributing the same in violation of law. By 

  
 4 

 
executing this Agreement, the Purchaser further represents that the Purchaser does not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or
grant participations to such Person or to any third Person, with respect to any of the Forward Purchase Shares. If the Purchaser was formed for the specific purpose of acquiring the Forward Purchase Shares, each of its equity owners is an accredited
investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act. For purposes of this Agreement, “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a
trust, an unincorporated organization, any other entity or any government or any department or agency thereof. 
 (f) Disclosure of
Information. The Purchaser has had an opportunity to discuss the Company’s business, management, financial affairs and the terms and conditions of the offering and sale of the Forward Purchase Shares, as well as the terms of the IPO, with
the Company’s management. 
 (g) Restricted Securities. The Purchaser understands that the offer and sale of the Forward Purchase
Shares to the Purchaser has not been, and will not be, registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the
investment intent and the accuracy of the Purchaser’s representations as expressed herein. The Purchaser understands that the Forward Purchase Shares are “restricted securities” under applicable U.S. federal and state securities laws
and that, pursuant to these laws, the Purchaser must hold the Forward Purchase Shares indefinitely unless they are registered with the SEC and qualified by state authorities, or an exemption from such registration and qualification requirements is
available. The Purchaser acknowledges that the Company has no obligation to register or qualify the Forward Purchase Shares, except pursuant to the Registration Rights. The Purchaser further acknowledges that if an exemption from registration or
qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Forward Purchase Shares, and requirements relating to the Company which are outside of
the Purchaser’s control, and which the Company is under no obligation and may not be able to satisfy. The Purchaser acknowledges that the Company filed the Registration Statement for the IPO with the SEC. The Purchaser understands that the
offering of the Forward Purchase Shares hereunder is not, and is not intended to be, part of the IPO, and that the Purchaser will not be able to rely on the protection of Section 11 of the Securities Act with respect to such offering of the
Forward Purchase Shares. 
 (h) No Public Market. The Purchaser understands that no public market now exists for the Forward Purchase
Shares, and that the Company has made no assurances that a public market will ever exist for the Forward Purchase Shares. 
 (i) High
Degree of Risk. The Purchaser understands that its agreement to purchase the Forward Purchase Shares involves a high degree of risk which could cause the Purchaser to lose all or part of its investment. 

(j) Accredited Investor. The Purchaser is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under
the Securities Act. 

  
 5 

 (k) Foreign Investors. If the Purchaser is not a United States person (as defined by
Section 7701(a)(30) of the U.S. Internal Revenue Code of 1986, as amended), the Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe
for the Forward Purchase Shares or any use of this Agreement, including (i) the legal requirements within its jurisdiction for the purchase of the Forward Purchase Shares, (ii) any foreign exchange restrictions applicable to such purchase,
(iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Forward Purchase Shares.
The Purchaser’s subscription and payment for and continued beneficial ownership of the Forward Purchase Shares will not violate any applicable securities or other laws of the Purchaser’s jurisdiction. 

(l) No General Solicitation. Neither the Purchaser, nor any of its officers, directors, employees, agents, stockholders or partners has
either directly or indirectly, including through a broker or finder, (i) to its knowledge, engaged in any general solicitation, or (ii) published any advertisement in connection with the offer and sale of the Forward Purchase Shares. 

(m) Residence. The principal place of business of the Purchaser is the office located at the address of the Purchaser set forth on the
signature page hereof. 
 (n) Non-Public Information. The Purchaser acknowledges its
obligations under applicable securities laws with respect to the treatment of material non-public information relating to the Company. 

(o) Adequacy of Financing. The Purchaser has available to it sufficient funds to satisfy its obligations under this Agreement. 

(p) Affiliation of Certain FINRA Members. The Purchaser is neither a person associated nor affiliated with any underwriter of the IPO
or, to its actual knowledge, any other member of the Financial Industry Regulatory Authority (“FINRA”) that is participating in the IPO. 

(q) No Other Representations and Warranties; Non-Reliance. Except for the specific
representations and warranties contained in this Section 2 and in any certificate or agreement delivered pursuant hereto, none of the Purchaser nor any person acting on behalf of the Purchaser nor any of the Purchaser’s affiliates (the
“Purchaser Parties”) has made, makes or shall be deemed to make any other express or implied representation or warranty with respect to the Purchaser and the offering, sale and purchase of the Forward Purchase Shares, and the
Purchaser Parties disclaim any such representation or warranty. Except for the specific representations and warranties expressly made by the Company in Section 3 of this Agreement and in any certificate or agreement delivered pursuant hereto,
the Purchaser Parties specifically disclaim that they are relying upon any other representations or warranties that may have been made by the Company, any person on behalf of the Company or any of the Company’s affiliates (collectively, the
“Company Parties”). 

  
 6 

 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and warrants
to the Purchaser as follows: 
 (a) Incorporation and Corporate Power. The Company is a corporation duly incorporated and validly
existing and in good standing under the laws of the Cayman Islands and has all requisite corporate power and authority to carry on its business as presently conducted and as proposed to be conducted. The Company has no subsidiaries. 

(b) Capitalization. The authorized share capital of the Company consists, as of the date hereof, of: 

(i) 500,000,000 Class A ordinary shares, none of which are issued and outstanding; 

(ii) 50,000,000 Class B ordinary shares of the Company, par value $0.0001 per share (the
“Class B ordinary shares”), 8,625,000 of which are issued and outstanding; and all of the outstanding Class B ordinary shares have been duly authorized, are fully paid and nonassessable and were issued in
compliance with all applicable laws; and 
 (iii) 5,000,000 shares of preferred stock, none of which are issued and
outstanding. 
 (c) Authorization. All corporate action required to be taken by the Company’s Board of Directors and shareholders
in order to authorize the Company to enter into this Agreement, and to issue the Forward Purchase Shares at the FPS Closing, has been taken or will be taken prior to the FPS Closing, as applicable. All action on the part of the shareholders,
directors and officers of the Company necessary for the execution and delivery of this Agreement, the performance of all obligations of the Company under this Agreement to be performed as of the FPS Closing, and the issuance and delivery of the
Forward Purchase Shares has been taken or will be taken prior to the FPS Closing, as applicable. This Agreement, when executed and delivered by the Company, shall constitute the valid and legally binding obligation of the Company, enforceable
against the Company in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of
creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or (iii) to the extent the indemnification provisions contained in the
Registration Rights may be limited by applicable federal or state securities laws. 
 (d) Valid Issuance of Forward Purchase Shares.

 (i) The Forward Purchase Shares, when issued, sold and delivered in accordance with the terms and for the consideration
set forth in this Agreement, will be validly issued, fully paid and nonassessable and free of all preemptive or similar rights, liens, encumbrances and charges with respect to the issue thereof and restrictions on transfer other than restrictions on
transfer specified under this Agreement, applicable state and federal securities laws and liens or encumbrances created by or imposed by the Purchaser. Assuming the accuracy of the representations of the Purchaser in this Agreement and subject to
the filings described in Section 3(e) below, the Forward Purchase Shares will be issued in compliance with all applicable federal and state securities laws. 

  
 7 

 (ii) No “bad actor” disqualifying event described in Rule
506(d)(1)(i)-(viii) of the Securities Act (a “Disqualification Event”) is applicable to the Company or, to the Company’s knowledge, any Company Covered Person (as defined below), except for a Disqualification Event as to which
Rule 506(d)(2)(ii)—(iv) or (d)(3), is applicable. “Company Covered Person” means, with respect to the Company as an “issuer” for purposes of Rule 506 promulgated under the Securities Act, any Person listed in the
first paragraph of Rule 506(d)(1). 
 (e) Governmental Consents and Filings. Assuming the accuracy of the representations and
warranties made by the Purchaser in this Agreement, no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the part
of the Company in connection with the consummation of the transactions contemplated by this Agreement, except for any filings pursuant to Regulation D of the Securities Act, applicable state securities laws, and pursuant to the Registration Rights.

 (f) Compliance with Other Instruments. The execution, delivery and performance of this Agreement and the consummation of the
transactions contemplated by this Agreement by the Company will not result in any violation or default (i) of any provisions of the Company’s certificate of incorporation, as it may be amended from time to time (the
“Charter”) or its other governing documents, (ii) of any instrument, judgment, order, writ or decree to which the Company is a party or by which the Company is bound, (iii) under any note, indenture or mortgage to which
the Company is a party or by which the Company is bound, (iv) under any lease, agreement, contract or purchase order to which the Company is a party or by which the Company is bound or (v) of any provision of federal or state statute, rule
or regulation applicable to the Company, in each case (other than clause (i)) which would have a material adverse effect on the Company or its ability to consummate the transactions contemplated by this Agreement. 

(g) Operations. As of the date hereof, the Company has not conducted, and prior to the IPO Closing the Company will not conduct, any
operations other than organizational activities and activities in connection with the IPO and offerings of the Forward Purchase Shares. 

(h) Foreign Corrupt Practices. Neither the Company, nor, to the knowledge of the Company, any director, officer, agent, employee or
other Person acting on behalf of the Company has, in the course of its actions for, or on behalf of, the Company (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political
activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of
1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee. 

  
 8 

 (i) Compliance with Anti-Money Laundering Laws. The operations of the Company are and
have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements and all applicable U.S. and non-U.S. anti-money laundering laws, rules and regulations,
including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the USA Patriot Act of 2001 and the applicable money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any
related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before any court or
governmental agency, authority or body or any arbitrator involving the Company with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened. 

(j) Absence of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board,
government agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company or any of the Company’s officers or directors, whether of a civil or criminal nature or otherwise,
in their capacities as such. 
 (k) No General Solicitation. Neither the Company, nor any of its officers, directors, employees,
agents or shareholders has either directly or indirectly, including through a broker or finder, (i) engaged in any general solicitation, or (ii) published any advertisement in connection with the offer and sale of the Forward Purchase
Shares. 
 (l) No Other Representations and Warranties; Non-Reliance. Except for the specific
representations and warranties contained in this Section 3 and in any certificate or agreement delivered pursuant hereto, none of the Company Parties has made, makes or shall be deemed to make any other express or implied representation or
warranty with respect to the Company, the offering, sale and purchase of the Forward Purchase Shares, the IPO or a potential Business Combination, and the Company Parties disclaim any such representation or warranty. Except for the specific
representations and warranties expressly made by the Purchaser in Section 2 of this Agreement and in any certificate or agreement delivered pursuant hereto, the Company Parties specifically disclaim that they are relying upon any other
representations or warranties that may have been made by any of the Purchaser Parties. 
 4. ADDITIONAL AGREEMENTS, ACKNOWLEDGEMENTS AND
WAIVERS OF THE PURCHASER. 
 (a) Trust Account. 

(i) The Purchaser hereby acknowledges that it is aware that the Company will establish a trust account (the “Trust
Account”) for the benefit of its public shareholders upon the IPO Closing. The Purchaser, for itself and its affiliates, hereby agrees that it has no right, title, interest or claim of any kind in or to any monies held in the Trust Account,
or any other asset of the Company as a result of any liquidation of the Company, except for redemption and liquidation rights, if any, the Purchaser may have in respect of any Class A ordinary shares issued in the IPO (the “Public
Shares”) held by it. 

  
 9 

 (ii) The Purchaser hereby agrees that it shall have no right of set-off or any right, title, interest or claim of any kind (“Claim”) to, or to any monies in, the Trust Account, and hereby irrevocably waives any Claim to, or to any monies in, the Trust Account
that it may have now or in the future, except for redemption and liquidation rights, if any, the Purchaser may have in respect of any Public Shares held by it. In the event the Purchaser has any Claim against the Company under this Agreement, the
Purchaser shall not pursue such Claim against the Trust Account or against the property or any monies in the Trust Account, except for redemption and liquidation rights, if any, the Purchaser may have in respect of any Public Shares held by it. 

(b) Redemption and Liquidation. The Purchaser hereby waives, with respect to any Forward Purchase Shares held by it, any redemption
rights it may have in connection with (i) the consummation of a Business Combination, including any such rights available in the context of a shareholder vote to approve such Business Combination and (ii) any shareholder vote to approve an
amendment to the Charter (A) to modify the substance or timing of the Company’s obligation to redeem 100% of the Company’s Class A ordinary shares if the Company does not complete its Business Combination within 24 months after
the closing of the IPO or (B) with respect to any other provisions relating to the rights of the Company’s Class A ordinary shares, it being understood that the Purchaser shall be entitled to redemption and liquidation rights with
respect to any Class A ordinary shares held by it other than the Forward Purchase Shares. 
 (c) Voting. The Purchaser hereby
agrees that if the Company seeks shareholder approval of a proposed Business Combination, then in connection with such proposed Business Combination, the Purchaser shall vote any Class A ordinary shares owned by it in favor of any proposed
Business Combination. If the Purchaser fails to vote any Class A ordinary shares it is required to vote hereunder in favor of a proposed Business Combination, the Purchaser hereby grants to the Company and any representative designated by the
Company without further action by the Purchaser a limited irrevocable power of attorney to effect such vote on behalf of the Purchaser, which power of attorney shall be deemed to be coupled with an interest. 

(d) No Short Sales. The Purchaser hereby agrees that neither it, nor any person or entity acting on its behalf or pursuant to any
understanding with it, will engage in any Short Sales with respect to securities of the Company prior to the Business Combination Closing. For purposes of this Section 4(b), “Short Sales” shall include, without limitation, all
“short sales” as defined in Rule 200 promulgated under Regulation SHO under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and all types of direct and indirect stock pledges (other than pledges in
the ordinary course of business as part of prime brokerage arrangements), forward sale contracts, options, puts, calls, swaps and similar arrangements (including on a total return basis), and sales and other transactions through non-U.S. broker dealers or foreign regulated brokers. 

  
 10 

 5. ADDITIONAL AGREEMENTS OF THE COMPANY. 

(a) No Material Non-Public Information. The Company agrees that no information provided to the
Purchaser in connection with this Agreement will, upon the IPO Closing, constitute material non-public information of the Company. 

(b) Nasdaq Listing. The Company will use commercially reasonable efforts to effect and maintain the listing of the Class A ordinary
shares on the Nasdaq Capital Market (or another national securities exchange). 
 (c) No Amendments to Charter. The amended and
restated certificate of incorporation of the Company will be in substantially the same form of Exhibit B hereto and will not be amended in any material respect prior to the IPO Closing without the Purchaser’s prior written consent. 

6. Lock-up. 
 (a) The
Purchaser agrees that it shall not Transfer (as defined below) any Class A ordinary shares until the earlier of (A) one year after the Business Combination Closing and (B) the date following the Business Combination Closing on which the Company
completes a liquidation, merger, share exchange or other similar transaction that results in all of the Company’s ordinary shareholders having the right to exchange their ordinary shares of the Company for cash, securities or other property.
Notwithstanding the foregoing, if, subsequent to a Business Combination, the closing price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations,
recapitalizations and the like) for any 20 trading days within any 30 trading day period commencing at least 150 days after the Business Combination Closing, the Class A Shares shall be released from the lockup referenced herein. For purposes of
this Sections 6, “Transfer” shall mean the (x) sale of, offer to sell, contract or agreement to sell, hypothecation, pledge, grant of any option to purchase or otherwise dispose of or agreement to dispose of, directly or indirectly, or
establishment or increase of a put equivalent position or liquidation with respect to or decrease of a call equivalent position (within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, and the rules and regulations of
the SEC promulgated thereunder) with respect to, any of the Securities (excluding any pledges in the ordinary course of business for bona fide financing purposes or as part of prime brokerage arrangements), (y) entry into any swap or other
arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any of the Securities, whether any such transaction is to be settled by delivery of such Securities, in cash or otherwise, or (z) public
announcement of any intention to effect any transaction specified in clause (x) or (y). 
 7. FPS CLOSING CONDITIONS. 

(a) The obligation of the Purchaser to purchase the Forward Purchase Shares at the FPS Closing under this Agreement shall be subject to the
fulfillment, at or prior to the FPS Closing of each of the following conditions, any of which, to the extent permitted by applicable laws, may be waived by the Purchaser: 

(i) The Business Combination shall be consummated substantially concurrently with, and immediately following, the purchase of
the Forward Purchase Shares; 
 (ii) The Company shall have delivered to such Purchaser a certificate evidencing the
Company’s good standing as a Cayman Islands corporation, as of a date within ten (10) Business Days of the Closing Date; 

(iii) The representations and warranties of the Company set forth in Section 3 of this Agreement shall have been true and
correct as of the date hereof and shall be true and correct as of the FPS Closing, as applicable, with the same effect as though such representations and warranties had been made on and as of such date (other than any such representation or warranty
that is made by its terms as of a specified date, which shall be true and correct as of such specified date), except where the failure to be so true and correct would not have a material adverse effect on the Company or its ability to consummate the
transactions contemplated by this Agreement; 
 (iv) The Company shall have performed, satisfied and complied in all material
respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the FPS Closing; and 

(v) No order, writ, judgment, injunction, decree, determination, or award shall have been entered or threatened by or with any
governmental, regulatory, or administrative authority or any court, tribunal, or judicial, or arbitral body, and no other legal restraint or prohibition shall be in effect or threatened, preventing the purchase by the Purchaser of the Forward
Purchase Shares. 

  
 11 

 (b) The obligation of the Company to sell the Forward Purchase Shares at the FPS Closing
under this Agreement shall be subject to the fulfillment, at or prior to the FPS Closing of each of the following conditions, any of which, to the extent permitted by applicable laws, may be waived by the Company: 

(i) The Business Combination shall be consummated substantially concurrently with, and immediately following, the purchase of
the Forward Purchase Shares; 
 (ii) The representations and warranties of the Purchaser set forth in Section 2 of this
Agreement shall have been true and correct as of the date hereof and shall be true and correct as of the FPS Closing, as applicable, with the same effect as though such representations and warranties had been made on and as of such date (other than
any such representation or warranty that is made by its terms as of a specified date, which shall be true and correct as of such specified date), except where the failure to be so true and correct would not have a material adverse effect on the
Purchaser or its ability to consummate the transactions contemplated by this Agreement; 
 (iii) The Purchaser shall have
performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Purchaser at or prior to the FPS Closing; and 

(iv) No order, writ, judgment, injunction, decree, determination, or award shall have been entered or threatened by or with any
governmental, regulatory, or administrative authority or any court, tribunal, or judicial, or arbitral body, and no other legal restraint or prohibition shall be in effect or threatened, preventing the purchase by the Purchaser of the Forward
Purchase Shares. 
 8. TERMINATION. This Agreement may be terminated at any time prior to the FPS Closing: 

(a) by mutual written consent of the Company and the Purchaser; or 

(b) automatically 

(i) if the IPO is not consummated on or prior to twelve months from the date of this Agreement; or 

(ii) if the Business Combination is not consummated within 24 months from the IPO Closing, or such later date as may be
approved by the Company’s shareholders in accordance with the Charter. 

  
 12 

 In the event of any termination of this Agreement pursuant to this Section 8, the FPS
Purchase Price (and interest thereon, if any), if previously paid, and all Purchaser’s funds paid in connection herewith shall be promptly returned to the Purchaser in accordance with written instructions provided by the Purchaser to the
Company, and thereafter this Agreement shall forthwith become null and void and have no effect, without any liability on the part of the Purchaser or the Company and their respective directors, officers, employees, partners, managers, members, or
shareholders and all rights and obligations of each party shall cease; provided, however, that nothing contained in this Section 8 shall relieve either party from liabilities or damages arising out of any fraud or willful breach
by such party of any of its representations, warranties, covenants or agreements contained in this Agreement. Section 4(a) shall survive termination of this Agreement. 

9. GENERAL PROVISIONS. 

(a) Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed
effectively given upon the earlier of actual receipt, and (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail or facsimile (if any) during normal business hours of the recipient, and if not sent
during normal business hours, then on the recipient’s next Business Day, (c) five (5) Business Days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) Business Day after
deposit with a nationally recognized overnight courier, freight prepaid, specifying next Business Day delivery, with written verification of receipt. All communications sent to the Company shall be sent to: Sound Point Acquisition Corp I, Ltd, 375
Park Avenue, New York, NY 10152, Attn: David Grill, email: dgrill@soundpointcap.com, with a copy to the Company’s counsel at: Gibson, Dunn & Crutcher LLP, 811 Main Street, Houston, TX 77002, Attn: Gerald M. Spedale, email:
GSpedale@gibsondunn.com. 
 All communications to the Purchaser shall be sent to the Purchaser’s address as set forth on the signature
page hereof, or to such e-mail address, facsimile number (if any) or address as subsequently modified by written notice given in accordance with this Section 9(a). 

(b) No Finder’s Fees. Other than fees payable to the underwriters of the IPO or any other investment bank or financial advisor who
assists the Company in sourcing targets for a Business Combination, which fees shall be the responsibility of the Company, each party represents that it neither is nor will be obligated for any finder’s fee or commission in connection with this
transaction. The Purchaser agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and the costs and expenses
of defending against such liability or asserted liability) for which the Purchaser or any of its officers, employees or representatives is responsible. The Company agrees to indemnify and hold harmless the Purchaser from any liability for any
commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers,
employees or representatives is responsible. 
 (c) Survival of Representations and Warranties. All of the representations and
warranties contained herein shall survive the FPS Closing. 

  
 13 

 (d) Entire Agreement. This Agreement, together with any documents, instruments and
writings that are delivered pursuant hereto or referenced herein, constitutes the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and supersedes all prior understandings, agreements, or
representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby. 

(e) Successors. All of the terms, agreements, covenants, representations, warranties, and conditions of this Agreement are binding upon,
and inure to the benefit of and are enforceable by, the parties hereto and their respective successors. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors
and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

(f) Assignments. Except as otherwise specifically provided herein, no party hereto may assign either this Agreement or any of its
rights, interests, or obligations hereunder without the prior written consent of the other party. Notwithstanding the foregoing, the Purchaser may assign and delegate all or a portion of its rights and obligations to purchase the Forward Purchase
Shares to one or more other persons upon the consent of the Company (which consent shall not be unreasonably conditioned, withheld or delayed); provided, however, that no consent of the Company shall be required if such assignment or
delegation is to an affiliate of Purchaser; provided, further, that no such assignment or delegation shall relieve the Purchaser of its obligations hereunder (including its obligation to purchase the Forward Purchase Shares hereunder)
and the Company shall be entitled to pursue all rights and remedies against the Purchaser subject to the terms and conditions hereof. 
 (g)
Counterparts. This Agreement may be executed in two or more counterparts, each of which will be deemed an original but all of which together will constitute one and the same instrument. 

(h) Headings. The section headings contained in this Agreement are inserted for convenience only and will not affect in any way the
meaning or interpretation of this Agreement. 
 (i) Governing Law. This Agreement, the entire relationship of the parties hereto, and
any dispute between the parties (whether grounded in contract, tort, statute, law or equity) shall be governed by, construed in accordance with, and interpreted pursuant to the laws of the State of New York. 

(j) Jurisdiction. The parties (i) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of New York
and to the jurisdiction of the United States District Court for the Southern District of New York for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (ii) agree not to commence any suit, action
or other proceeding arising out of or based upon this Agreement except in state courts of New York or the United States District Court for the Southern District of New York, and (iii) hereby waive, and agree not to assert, by way of motion, as
a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or
proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 

  
 14 

 (k) WAIVER OF JURY TRIAL. THE PARTIES HERETO HEREBY WAIVE ANY RIGHT TO A
JURY TRIAL IN CONNECTION WITH ANY LITIGATION PURSUANT TO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY. 
 (l)
Amendments. This Agreement may not be amended, modified or waived as to any particular provision, except with the prior written consent of the Company and the Purchaser. 

(m) Severability. The provisions of this Agreement will be deemed severable and the invalidity or unenforceability of any provision will
not affect the validity or enforceability of the other provisions hereof; provided that if any provision of this Agreement, as applied to any party hereto or to any circumstance, is adjudged by a governmental authority, arbitrator, or
mediator not to be enforceable in accordance with its terms, the parties hereto agree that the governmental authority, arbitrator, or mediator making such determination will have the power to modify the provision in a manner consistent with its
objectives such that it is enforceable, and/or to delete specific words or phrases, and in its reduced form, such provision will then be enforceable and will be enforced. 

(n) Expenses. Each of the Company and the Purchaser will be responsible for payment of its own costs and expenses incurred in connection
with the preparation, execution and performance of this Agreement and the consummation of the transactions contemplated hereby, including all fees and expenses of agents, representatives, financial advisors, legal counsel and accountants. The
Company shall be responsible for the fees of its transfer agent; stamp taxes and all of The Depository Trust Company’s fees associated with the issuance and resale of the Forward Purchase Shares. 

(o) Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. If an ambiguity or
question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the parties hereto and no presumption or burden of proof will arise favoring or disfavoring any party hereto because of the authorship of any
provision of this Agreement. Any reference to any federal, state, local, or foreign law will be deemed also to refer to law as amended and all rules and regulations promulgated thereunder, unless the context requires otherwise. The words
“include,” “includes,” and “including” will be deemed to be followed by “without limitation.” Pronouns in masculine, feminine, and neuter genders will be construed to include any
other gender, and words in the singular form will be construed to include the plural and vice versa, unless the context otherwise requires. The words “this Agreement,” “herein,” “hereof,”
“hereby,” “hereunder,” and words of similar import refer to this Agreement as a whole and not to any particular subdivision unless expressly so limited. The parties hereto intend that each representation, warranty,
and covenant contained herein will have independent significance. If any party hereto has breached any representation, warranty, or covenant contained herein in any respect, the fact that there exists another representation, warranty or covenant
relating to the same subject matter (regardless of the relative levels of specificity) which such party hereto has not breached will not detract from or mitigate the fact that such party hereto is in breach of the first representation, warranty, or
covenant. 

  
 15 

 (p) Waiver. No waiver by any party hereto of any default, misrepresentation, or
breach of warranty or covenant hereunder, whether intentional or not, may be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder or affect in any way any rights arising because of any
prior or subsequent occurrence. 
 (q) Confidentiality. Except as may be required by law, regulation or applicable stock exchange
listing requirements, unless and until the transactions contemplated hereby and the terms hereof are publicly announced or otherwise publicly disclosed by the Company, the parties hereto shall keep confidential and shall not publicly disclose the
existence or terms of this Agreement. 
 (r) Specific Performance. The Purchaser agrees that irreparable damage may occur in the event
any provision of this Agreement was not performed by the Purchaser in accordance with the terms hereof and that the Company shall be entitled to specific performance of the terms hereof, in addition to any other remedy at law or equity. 

  
 16 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement to be effective as
of the date first set forth above. 
  

			
	PURCHASER:
	
	[•]
		
	By:	 	
                     

	Name:
	Title:

  

			
	Address for Notices:
	
	 Attention:
 Email:

	
	with a copy (which shall not constitute notice) to:
	
	 Attn:
 Email:

Fax:

  

			
	COMPANY:
	
	SOUND POINT ACQUISITION CORP I, LTD
		
	By:	 	  

	Name:	 	Stephen Ketchum
	Title:	 	Chief Executive Officer

  
 [Signature Page to
Forward Purchase Agreement] 

 Exhibit A 

Registration Rights 
 1. Within thirty
(30) days after the Business Combination Closing, the Company shall use reasonable best efforts (i) to file a registration statement on Form S-3 for the resale (including any successor registration
statement covering the resale of the Registrable Securities, a “Resale Shelf”) of (x) the Forward Purchase Shares and (y) any other equity security of the Company issued or issuable with respect to the securities referred
to in clause (x) by way of a share capitalization or share split or in connection with a combination of shares, recapitalization, merger, consolidation or reorganization (collectively, for so long as such securities are held by the Purchaser or
its assignees under the Agreement (each, a “Holder”), the “Registrable Securities”) pursuant to Rule 415 under the Securities Act; provided that if Form S-3 is
unavailable for such a registration, the Company shall cause such Resale Shelf to be on Form S-1 or on another appropriate form and undertake to convert the Resale Shelf to or refile the Resale Shelf on Form S-3 as soon as such form is available, (ii) to cause the Resale Shelf to be declared effective under the Securities Act promptly thereafter, but in no event later than ninety (90) days after the initial
filing of the Resale Shelf, and (iii) to maintain the effectiveness of such Resale Shelf with respect to the Registrable Securities until the earlier of (A) the date on which such securities are no longer Registrable Securities and
(B) the date all of the Registrable Securities covered by the Resale Shelf can be sold publicly without restriction or limitation under Rule 144 under the Securities Act and without the requirement to be in compliance with Rule 144(c)(1) under
the Securities Act. 
 2. The Holders may, after the Resale Shelf becomes effective, deliver a written notice to the Company (the
“Underwritten Offering Notice”) specifying that the sale of some or all of the Registrable Securities subject to the Resale Shelf is intended to be conducted through a firm commitment underwritten offering (an “Underwritten
Offering”); provided, however, that the Holders of Registrable Securities may not, without the Company’s prior written consent, (i) launch an Underwritten Offering the anticipated gross proceeds of which shall be
less than $30,000,000 (unless the Holders are proposing to sell all of their remaining Registrable Securities), (ii) launch more than three Underwritten Offerings at the request of the Holders within any three-hundred sixty-five (365) day-period or (iii) launch an Underwritten Offering within the period commencing fourteen (14) days prior to and ending two (2) days following the Company’s scheduled earnings release
date for any fiscal quarter or year. In the event of an Underwritten Offering, the Holders representing a majority-in-interest of the Registrable Securities to be
included in such Underwritten Offering shall select the managing underwriter(s) for the Underwritten Offering; provided that the choice of such managing underwriter(s) shall be subject to the consent of the Company, which is not to be
unreasonably withheld, conditioned or delayed. If the underwriter(s) for any Underwritten Offering pursuant to this paragraph 2 of this Exhibit A (each, a “Secondary Offering”) advise the Company and the Holders that, in their good
faith opinion, marketing factors require a limitation on the number of securities that may be included in such Secondary Offering, the number of securities to be so included shall be allocated as follows: (i) first, to the Holders that have
requested to participate in such Secondary Offering, allocated pro rata among such Holders on the basis of the percentage of the Registrable Securities requested to be included in such Secondary Offering by such Holders, and (ii) second,
to the holders of any other securities of the Company that have been requested to be so included. 

  
 A-1 

 3. Upon receipt of prior written notice by any Holder that they intend to effect a sale of
Registrable Securities held by them as are then registered pursuant to the Resale Shelf, the Company shall use its reasonable best efforts to cooperate in such sale (whether or not such sale constitutes an Underwritten Offering), including by
amending or supplementing the prospectus related to such Resale Shelf as may be reasonably requested by such Holder for so long as such Holder holds Registrable Securities. 

4. In the event the Company is prohibited by applicable rule, regulation or interpretation by the staff (the “Staff”) of the
Securities and Exchange Commission (the “SEC”) from registering all of the Registrable Securities on the Resale Shelf or the Staff requires that any Holder be specifically identified as an “underwriter” in order to permit
such registration statement to become effective, and such Holder does not consent in writing to being so named as an underwriter in such registration statement, the number of Registrable Securities to be registered on the Resale Shelf will be
reduced on a pro rata basis among all Holders to be so included, unless otherwise required by the Staff, so that the number of Registrable Securities to be registered is permitted by the Staff and such Holder is not required to be named as an
“underwriter”; provided that any Registrable Securities not registered due to this paragraph 4 shall thereafter as soon as allowed by the SEC guidance be registered to the extent the prohibition no longer is applicable. 

5. If at any time the Company proposes to file a registration statement (a “Registration Statement”) on its own behalf, or on
behalf of any Persons other than the Holders who have registration rights (“Other Holders”), relating to an Underwritten Offering of Class A ordinary shares (a “Company Offering”), then the Company will provide
the Holders with notice in writing (an “Offer Notice”) at least three (3) Business Days prior to such filing, which Offer Notice will offer to include in the Registration Statement the Registrable Securities held by each Holder
(the “Piggyback Securities”). Within three (3) Business Days after receiving the Offer Notice, each Holder may make a written request (a “Piggyback Request”) to the Company to include some or all of such
Holder’s Registrable Securities in the Registration Statement. If the underwriter(s) for any Company Offering advise the Company that, in their good faith opinion, marketing factors require a limitation on the number of securities that may be
included in the Company Offering, the number of securities to be so included shall be allocated as follows: (i) first, to the Company and the Other Holders, if any; and (ii) second, to the Holders and any other holders of similar piggyback
rights, based pro rata on the value of the securities requested to be sold in such Company Offering by each requesting holder. 
 6. In
connection with any Underwritten Offering, the Company shall enter into such customary agreements and take all such other actions in connection therewith (including those reasonably requested by Holders representing a
majority-in-interest of the Registrable Securities to be included in such Underwritten Offering) in order to facilitate the disposition of such Registrable Securities as
are reasonably necessary or required, and in such connection enter into a customary underwriting agreement that provides for customary opinions, comfort letters and officer’s certificates and other customary deliverables. 

  
 A-2 

 7. The Company shall pay all fees and expenses incident to the performance of or compliance
with its obligation to prepare, file and maintain the Resale Shelf (including the fees of its counsel and accountants). The Company shall also pay all Registration Expenses. For purposes of this paragraph 7, “Registration Expenses”
shall mean the out-of-pocket expenses of any Secondary Offering and any Company Offering, including, without limitation, the following: (i) all registration and
filing fees (including fees with respect to filings required to be made with FINRA and any securities exchange on which the Registrable Securities are then listed); (ii) fees and expenses of compliance with securities or blue sky laws (including
reasonable fees and disbursements of counsel for the underwriters in connection with blue sky qualifications of the Registrable Securities); (iii) printing, messenger, telephone and delivery expenses; (iv) reasonable fees and disbursements of
counsel for the Company; (v) reasonable fees and disbursements of all independent registered public accountants of the Company; and (vi) reasonable fees and expenses of one (1) legal counsel selected by Holders representing a majority-in-interest of the Registrable Securities participating in any such Secondary Offering not to exceed $75,000 per Secondary Offering, but shall not include any
incremental selling expenses relating to the sale of Registrable Securities, such as underwriters’ commissions and discounts, brokerage fees, underwriter marketing costs and, other than as set forth in clause (vi) of this paragraph 7, the
fees and expenses of any legal counsel representing the Holders; and provided that the Company shall only be responsible for expenses under clause (vi) with respect to two Secondary Offerings in any consecutive three-hundred sixty-five (365) day-period. 
 8. The Company may suspend the use of a prospectus included in the Resale Shelf
by furnishing to the Holders a written notice (“Suspension Notice”) stating that in the good faith judgment of the Company, it would be either (i) prohibited by the Company’s insider trading policy (as if the Holders were
covered by such policy) or (ii) materially detrimental to the Company and its shareholders for such prospectus to be used at such time. The Company’s right to suspend the use of such prospectus under clause (ii) of the preceding
sentence may be exercised for a period of not more than ninety (90) days after the date of such notice to the Holders; provided that such period may be extended for an additional thirty (30) days with the consent of Holders
representing a majority-in-interest of the Registrable Securities, which consent shall not be unreasonably withheld; provided, further, that such right to
suspend the use of a prospectus shall be exercised by the Company not more than once in any twelve (12) month period. The Holders shall not effect any sales of Registrable Securities pursuant to the Resale Shelf at any time after they have
received a Suspension Notice from the Company and prior to receipt of an End of Suspension Notice (as defined below). The Holders may recommence effecting sales of the Registrable Securities pursuant to the Resale Shelf following further written
notice to such effect (an “End of Suspension Notice”) from the Company to the Holders. The Company shall act in good faith to permit any suspension period contemplated by this paragraph to be concluded as promptly as reasonably
practicable. 
 9. The Holders agree that, except as required by applicable law, the Holders shall treat as confidential the receipt of any
Suspension Notice (provided that in no event shall such notice contain any material nonpublic information of the Company) hereunder and shall not disclose or use the information contained in such Suspension Notice (including the existence of such
Suspension Notice) without the prior written consent of the Company until such time as the information contained therein is or becomes public, other than as a result of disclosure by a Holder of Registrable Securities in breach of the terms of this
Agreement. 

  
 A-3 

 10. The Company shall indemnify and hold harmless the Holders, their respective directors
and officers, partners, members, managers, employees, agents, and representatives and each person, if any, who controls a Holder within the meaning of the Securities Act and the Exchange Act and any agent thereof (collectively, “Indemnified
Persons”), to the fullest extent permitted by applicable law, from and against any losses, claims, damages, liabilities, joint or several, costs (including reasonable costs of preparation and reasonable attorneys’ fees) and expenses,
judgments, fines, penalties, interest, settlements or other amounts arising from any and all claims, demands, actions, suits or proceedings, whether civil, criminal, administrative or investigative, in which any Indemnified Person may be involved,
or is threatened to be involved, as a party or otherwise, under the Securities Act or otherwise (collectively, “Losses”), promptly as incurred, arising out of, based upon or resulting from any untrue statement or alleged untrue
statement of any material fact contained in the Resale Shelf (or any amendment or supplement thereto), the related prospectus, or any amendment or supplement thereto, or arise out of, are based upon or resulting from the omission or alleged omission
to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading; provided, however, that the Company shall not be liable
in any such case or to any Indemnified Person to the extent that any such Loss arises out of, is based upon or results from an untrue statement or alleged untrue statement or omission or alleged omission or so made in reliance upon or in conformity
with information furnished by or on behalf of such Indemnified Person in writing specifically for use in the preparation of the Resale Shelf, the related prospectus, or any amendment or supplement thereto. Such indemnity shall remain in full force
and effect regardless of any investigation made by or on behalf of such Indemnified Person, and shall survive the transfer of such securities by the Purchaser. 

11. The Company’s obligation under paragraph 1 of this Exhibit A is subject to each Holder’s furnishing to the Company in writing
such information as the Company reasonably requests for use in connection with the Resale Shelf, the related prospectus, or any amendment or supplement thereto. Each Holder shall indemnify the Company, its officers, directors, managers, employees,
agents and representatives, and each person who controls the Company (within the meaning of the Securities Act) against any losses, claims, damages, liabilities and expenses resulting from any untrue statement or alleged untrue statement of material
fact contained in the Resale Shelf, the related prospectus, or any amendment or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading, but
only to the extent that such untrue statement or omission is contained in any information so furnished in writing by such Holder expressly for inclusion in such Resale Shelf, related prospectus or amendment or supplement thereto, as applicable;
provided that the obligation to indemnify shall be individual, not joint and several, and shall be limited to the net amount of proceeds received by the applicable Holder from the sale of Registrable Securities pursuant to the Resale Shelf.

 12. The Company shall cooperate with the Holders, to the extent the Registrable Securities become freely tradable, to facilitate the
timely preparation and delivery of certificates (not bearing any restrictive legend) representing the Registrable Securities to be offered pursuant to a Resale Shelf and enable such certificates to be in such denominations or amounts, as the case
may be, as the Holders may reasonably request and registered in such names as each Holder may request. 

  
 A-4 

 13. If requested by Holders representing a majority-in-interest of the Registrable Securities, the Company shall as soon as practicable, subject to any Suspension Notice, (i) incorporate in a prospectus supplement or post-effective amendment such
information as each Holder reasonably requests to be included therein relating to the sale and distribution of Registrable Securities, including, without limitation, information with respect to the number of Registrable Securities being offered or
sold, the purchase price being paid therefor and any other terms of the offering of the Registrable Securities to be sold in such offering; (ii) make all required filings of such prospectus supplement or post-effective amendment after being
notified of the matters to be incorporated in such prospectus supplement or post-effective amendment; and (iii) supplement or make amendments to any Registration Statement if reasonably requested by Holders representing a majority-in-interest of the Registrable Securities. 
 14. As long
as Registrable Securities are outstanding, the Company, at all times while it shall be reporting under the Exchange Act, covenants to file timely (or obtain extensions in respect thereof and file within the applicable grace period) all reports
required to be filed by the Company after the date hereof pursuant to Sections 13(a) or 15(d) of the Exchange Act, and to promptly furnish the Holders with true and complete copies of all such filings, unless filed through the SEC’s EDGAR
system. The Company further covenants that it shall take such further action as the Holders may reasonably request, all to the extent required from time to time, to enable the Holders to sell the Class A ordinary shares and Warrants held by the
Holders without registration under the Securities Act within the limitation of the exemptions provided by Rule 144 promulgated under the Securities Act, including providing any legal opinions, to the extent such exemption is available to the
Purchaser at such time. Upon the request of any Holder, the Company shall deliver to such Holder a written certification of a duly authorized officer as to whether it has complied with such requirements. 

  
 A-5 

 Exhibit B 

Form of Amended and Restated Memorandum and Articles of Association of the Company 

See attached. 

  
 B-1Exhibit 10.01

 

EMPLOYMENT AGREEMENT

 

This EMPLOYMENT AGREEMENT (this
 “Agreement”) is made as of January 26, 2022 by and between Adaptimmune, LLC (the “Company”), a limited
liability corporation and wholly-owned subsidiary of Adaptimmune Limited, and Cintia Piccina, an individual residing at [*****] (“Executive”).

 

WHEREAS the Company and Executive
desire to enter into this Agreement to establish and govern the terms and conditions of Executive’s employment by the Company;

 

NOW THEREFORE, in consideration
of the promises and mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto agree as follows:

 

1.     Employment.
The Company agrees to employ Executive and Executive agrees to provide services to the Company pursuant to this Agreement from January
31, 2022 (“Commencement of Employment”) until the termination of Executive’s employment hereunder pursuant to
Section 5. The period from Commencement of Employment through the date of Executive’s termination of employment shall be
referred to as the “Employment Period.”

 

2.     Position
and Duties.

 

(a)    
During the Employment Period, Executive shall be employed by the Company and shall serve as the Chief Commercial Officer of Adaptimmune
Therapeutics plc (the “PLC”) and in such capacity shall have the normal duties, responsibilities, functions and authority
of a Chief Commercial Officer, subject to the power and authority of the Chief Executive Officer and the board of directors or the remuneration
committee of such board of directors, as applicable (the “Board”) of the PLC to expand or limit such duties, responsibilities,
functions and authority, and the power and authority of the Board to overrule actions of officers of the Group. During the Employment
Period, Executive shall render such services to the Group which are consistent with Executive’s position and as the Chief Executive
Officer and the Board may from time to time direct.

 

In this Agreement, “Group”
means the PLC and its subsidiaries from time to time and “Group Company” means a company which is a member of the Group
and includes the Company.

 

(b)    
During the Employment Period, Executive shall report to the Chief Executive Officer and shall devote her best efforts and her full business
time and attention to the business and affairs of the Group. Executive shall perform her duties, responsibilities and functions to the
best of her abilities in a diligent, trustworthy, professional and efficient manner, shall comply with the policies and procedures of
the Company and of the PLC and shall comply with all applicable federal, state and/or local laws. In performing her duties and exercising
her authority under this Agreement, Executive shall develop, support and implement the business and strategic plans approved from time
to time by the Board. So long as Executive is employed by the Company, Executive shall not, without the prior written consent of the Board,
accept other employment or perform other services for compensation, which the Board reasonably considers may be, or become harmful to
the interests of the Company or any Group Company or which might reasonably be considered to interfere with Executive’s duties under
this Agreement. Notwithstanding the foregoing, nothing in this Agreement shall preclude Executive from engaging in educational, charitable,
political, professional and civic activities, provided that such engagement does not interfere with Executive’s duties and responsibilities
hereunder.

 

(c)          
During the Employment Period, Executive’s primary work location shall be Philadelphia, Pennsylvania; provided, however, that Executive
shall travel to other locations and countries as and when required by the Board including, but not limited to, travel to the Group’s
affiliate offices in the United Kingdom.

 

     

     

    

 

3.     At-Will
Relationship. Executive’s employment with the Company is at-will and not for any specified period and may be terminated by
either Executive or the Company at any time for any or no reason, subject to Section 5 of this Agreement. Nothing in this
Agreement is intended to or should be construed to contradict, modify or alter this at-will employment relationship.

 

4.     Compensation
and Benefits.

 

(a)    
Base Salary. During the Employment Period, Executive’s base salary initially, with effect from January 31, 2022 shall be
$445,000 per annum, which may be modified by the Company in its sole discretion (the “Base Salary”), and which shall
be payable by the Company in regular installments in accordance with the Company’s payroll practices in effect from time to time,
less applicable deductions and withholding as required by law. For the avoidance of doubt, in any partial calendar year in the Employment
Period, the Base Salary shall be prorated to reflect the period of time for which Executive is actually employed by the Company pursuant
to this Agreement. During the Employment Period, the Base Salary shall be reviewed annually by the Company in accordance with the guidelines
and procedures of the Group applicable to similarly situated executives with the first such review effective January 2023.

 

(b)    
Bonus.

 

(i) Sign-on Bonus.
The Company shall pay Executive a one-off bonus of $150,000 of which $100,000 shall be paid on the first payroll date in the month immediately
following the month when Executive assumes the role of Chief Commercial Officer (the “Initial Installment Sign-on Bonus”)
and $50,000 shall be paid on the first payroll date immediately following the date that is the first anniversary of the Commencement of
Employment (the “Final Installment Sign-on Bonus”). The Initial Installment Sign-on Bonus payment and the Final Installment
Sign-on Bonus payment shall be paid to Executive less applicable deductions and withholding as required by law.

 

In the event that
the employment under this Agreement is terminated by the Company for Cause or by Executive if Executive resigns other than for Good Reason
on a date that precedes the first anniversary of the Commencement of Employment date, Executive agrees that she shall be liable to repay
the full (gross) amount of the Initial Installment Sign-on Bonus by no later than the seventh day following the date of termination of
the employment under this Agreement. In the event that the employment under this Agreement is terminated by the Company for Cause or by
Executive if Executive resigns other than for Good Reason on a date that precedes the second anniversary of the Commencement of Employment
date, Executive agrees that she shall be liable to repay the full (gross) amount of the Final Installment Sign-on Bonus by no later than
the seventh day following the date of termination of the employment under this Agreement. Executive agrees that in order to facilitate
any such repayment, whether of the Initial Installment Sign-on Bonus or the Final Installment Sign-on Bonus, the Company may elect, in
its absolute discretion, to make deductions from any amounts due to be paid to Executive.

 

For purposes of this Agreement,
 “Cause” shall mean with respect to Executive one or more of the following: (i) acts or omissions constituting gross
negligence, recklessness or willful misconduct on the part of Executive with respect to Executive's obligations or otherwise relating
to the business of the Group; (ii) Executive's material breach of the PLC or any Group Company rules, policies and/or procedures; (iii)
Executive's material insubordination or material non-performance or willful neglect of assigned duties; (iv) acts or omissions which bring
the reputation of the PLC or any Group Company into material disrepute; (v) any act or omission by Executive aiding or abetting a competitor,
supplier or customer of the PLC and/or any of its subsidiaries or affiliates to the material disadvantage or detriment of the PLC and/or
any of its subsidiaries or affiliates; (vi) Executive’s commission of fraud, misappropriation, embezzlement or theft; or (vii) Executive’s
material breach of this Agreement, including, but not limited to, violation of any of the restrictive covenants set forth in this Agreement.

 

    2

     

    

 

For purposes of this
Agreement, “Good Reason” shall mean that Executive has complied with the “Good Reason Process”
(hereinafter defined) following the occurrence of any of the following events: (i) the Company materially reduces the amount of the
Base Salary, except for across-the-board salary reductions based on the Group’s financial performance similarly affecting all
or substantially all senior management employees of each and every Group Company or as otherwise agreed with Executive; (ii) the
Company breaches its material obligations under this Agreement, or (iii) the Company materially reduces Executive’s authority,
duties or responsibilities without Executive’s consent. “Good Reason Process” shall mean that: (i)
Executive notifies the Company in writing of the first occurrence of one of the Good Reason conditions within sixty (60) days of the
first occurrence of such condition; (ii) Executive cooperates in good faith with the Company’s efforts, for a period not less
than thirty (30) days following such notice (the “Cure Period”), to remedy the condition; (iii) notwithstanding
such efforts, the Good Reason condition continues to exist; and (iv) Executive terminates her employment within sixty (60) days
after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed
not to have occurred and no right to terminate for Good Reason shall exist. There is however no obligation on the Company to remedy
the condition that is considered by Executive to be Good Reason.

 

(ii) Annual Bonus.
Subject to the terms of the Executive Severance Policy of the PLC, in force from time to time (the “Executive Severance Policy”),
in addition to the Base Salary, Executive will be eligible to receive a bonus following the end of each calendar year that ends during
the Employment Period (“Annual Bonus”), subject to: (i) objective criteria set forth by the Board or an authorized
delegate thereof on an annual basis; and (ii) the overall performance of the Group. The initial target Annual Bonus with effect from January
31, 2022 shall be forty-five percent (45%) of Executive’s Base Salary. The Annual Bonus shall be pro-rated for any year of employment
and paid in a single lump sum no later than March 15, of the year following the calendar year in which the Annual Bonus, if any, was earned.
For clarity, any Annual Bonus payment made to Executive shall be purely discretionary and shall not form part of Executive’s contractual
compensation under this Agreement. The first review of the target Annual Bonus percentage will occur in January 2023 and thereafter the
target Annual Bonus percentage shall be reviewed on an annual basis. If the Company makes an Annual Bonus payment to Executive in respect
of a particular calendar year, it shall not be obliged to make subsequent Annual Bonus payments in respect of subsequent calendar years.

 

Executive must be
employed by the Company on December 31st of the calendar year on which the Annual Bonus is based in order to be eligible to
receive the Annual Bonus. Any Annual Bonus payments shall be paid to Executive less applicable deductions and withholding as required
by law. Nothing in this Agreement will preclude the Board from changing or altering the objective criteria referred to under Section
4(b)(i), in whole or in part, in the Board’s sole discretion.

 

(c)          
Stock Options. During the Employment Period, Executive shall be eligible to participate in the equity plans sponsored and/or maintained
by the Company and its affiliates from time to time, in accordance with the terms of any such plans, at the sole and absolute discretion
of the Company and the Board. On or around January 31, 2022 or such other date as the Board may determine and subject to the rules of
the relevant equity plan and any applicable legal or regulatory requirements, Executive shall be awarded “market value” options
to acquire ordinary shares in the PLC and RSU-style options to acquire ordinary shares in the PLC on condition that, at the time of the
award of such stock options, Executive continues to serve as the Chief Commercial Officer of the PLC and remains employed by the Company
and is not under notice of termination (given or received). A portion of the options shall vest over a period of six months from the date
of grant and the remainder of the options shall vest over a period of four years from the date of grant. The market value options shall
have an exercise price per ordinary share of not less than one sixth of the closing trading price of an American Depositary Share on the
last business day prior to the date of grant, translated from USD to GBP, and the RSU-style options shall have an exercise price of £0.001
per ordinary share.

 

(d)          
Employee Benefits. During the Employment Period, Executive shall be entitled to participate in all of the Company’s then-existing
employee benefit programs for which senior executive employees of the Company are generally eligible. Nothing in this Agreement will preclude
the Company from changing, altering or terminating any of the plans or programs for which senior executive employees of the Company are
eligible, in whole or in part, in the Company’s sole discretion.

 

    3

     

    

 

(e)          
Vacation. During the Employment Period, Executive shall receive paid vacation per calendar year (prorated to reflect the period
of time for which Executive is actually employed by the Company pursuant to this Agreement), to be accrued and taken in accordance with
the Company’s then-existing vacation policies. In the vacation year in which her employment terminates, Executive's entitlement
to vacation shall accrue on a pro-rata basis for each complete month of service during the relevant year. If, on the termination of the
employment, Executive has exceeded her accrued vacation entitlement, the excess may be deducted from any sums due to her unless the amounts
due to her constitute “deferred compensation” for purposes of Section 409A of the Internal Revenue Code. If Executive has
any unused vacation entitlement, the Company may either require Executive to take such unused vacation during any notice period or to
accept payment in lieu of vacation. Any payment in lieu of vacation shall only be made in respect of vacation accrued during Executive's
final vacation year.

 

(f)     
Business Equipment. During the Employment Period, the Company shall provide Executive with equipment for business use in accordance
with the Company’s then-existing device policy (“Business Equipment”). The Company also agrees to pay reasonable
related monthly service charges for the Business Equipment. Executive understands that the Business Equipment provided by the Company
is for business use and will remain the property of the Company. Upon termination of employment or on demand by the Company at any time,
Executive agrees to immediately return the Business Equipment without copying, deleting or otherwise modifying any data, documents or
information stored on the Business Equipment.

 

5.     Notice
of Termination

 

(a)    
Notice of Termination. Subject to the terms of this Agreement, the Employment Period and Executive’s employment with the
Company may be terminated by the Company immediately at any time and for any or no reason, and by Executive for any reason including but
not limited to Good Reason, on provision of sixty (60) days written notice. Any termination of employment by the Company or by Executive
under this Section 5 shall be communicated by a written notice to the other party hereto indicating the specific termination provision
in this Agreement relied upon (a “Notice of Termination”).

 

(b)    
The Executive Severance Policy as in force from time to time shall apply to Executive in relation to the Employment. Such policy may be
amended or terminated in accordance with the terms of the policy, save that where any proposed amendment or termination substantially
reduces the rights of Executive following the termination of Executive’s employment: (i) the Company will consult with Executive
on such proposed amendment or termination; and (ii) any such substantial reduction in the rights or benefits of Executive must be agreed
with Executive. Where, following consultation, Executive does not agree to any such proposed amendment or termination, then the Executive
Severance Policy shall continue in full force and effect without such proposed amendment or termination.

 

6.     Confidential
Information.

 

(a)    
Executive shall not, except as may be required to perform Executive’s duties hereunder or as required by applicable law, during
the Employment Period and after employment ends (regardless of the reason), without limitation in time or until such information shall
have become public other than by Executive’s unauthorized disclosure, disclose to others or use, whether directly or indirectly,
any non-public confidential or proprietary information with respect to the PLC or any Group Company, including, without limitation, their
business relationships, negotiations and past, present and prospective activities, methods of doing business, know-how, trade secrets,
data, formulae, product designs and styles, product development plans, customer lists, investors, and all papers, resumes and records
(including computer records) of the documents containing such information (“Confidential Information”). Executive stipulates
and agrees that as between Executive and the PLC or any Group Company the foregoing matters are important and that material and confidential
proprietary information and trade secrets affect the successful conduct of the businesses of the PLC or any Group Company (and any successor
or assignee of the PLC or any Group Company). Nothing about the foregoing shall preclude Executive from testifying truthfully in any forum
or from providing truthful information to any government agency or commission.

 

(b)    
Executive agrees not to remove from the Company’s premises any property of the PLC or any Group Company including, but not limited
to, documents, records, or materials containing any Confidential Information, except as necessary to perform Executive’s work for
the Group.

 

    4

     

    

 

(c)    
Executive agrees to deliver or return to the Company, at the Company’s request at any time or upon termination of Executive’s
employment (regardless of the reason): (i) all documents, computer tapes and disks, records, lists, data, drawings, prints, notes and
written information (and all copies thereof) furnished by or on behalf of or for the benefit of the PLC or any Group Company or prepared
by Executive during the term of Executive’s employment by the Company, regardless of whether Confidential Information is contained
therein; and (ii) all physical property of the PLC or any Group Company which Executive received in connection with Executive’s
employment with the Company including, without limitation, credit cards, passes, door and file keys, and computer hardware and software
existing in tangible form.

 

(d)          
Executive represents and warrants to the Company that Executive took nothing with her which belonged to any former employer when Executive
left her prior position and that Executive has nothing that contains any information which belongs to any former employer. If at any time
Executive discovers this is incorrect, Executive shall promptly return any such materials to Executive’s former employer. The Company
does not want any such materials, and Executive shall not be permitted to use or refer to any such materials in the performance of Executive’s
duties hereunder.

 

7.     Work
Product and Intellectual Property, Inventions and Patents.

 

(a)   For purposes
of this Agreement, “Work Product” shall include (i) all works, materials, ideas, innovations, inventions, discoveries,
techniques, methods, processes, formulae, compositions, developments, improvements, technology, know-how, algorithms, data and data files,
computer process systems, computer code, software, databases, hardware configuration information, research and development projects, experiments,
trials, assays, lab books, test results, specifications, formats, designs, drawings, blueprints, sketches, artwork, graphics, documents,
records, writings, reports, machinery, prototypes, models, sequences, and components; (ii) all tangible and intangible embodiments of
the foregoing, of any kind or format whatsoever, including in printed and electronic media; and (iii) all Intellectual Property Rights
(as defined below) associated with or related to the foregoing.

 

“Company Work Product”
shall include all Work Product that Executive partially or completely creates, makes, develops, discovers, derives, conceives, reduces
to practice, authors, or fixes in a tangible medium of expression, whether solely or jointly with others and whether on or off the Group’s
premises, in connection with the Group’s business (w) while employed by the Company, or (x) with the use of the time, materials,
or facilities of the Group, or (y) relating to any product, service, or activity of the Group of which Executive has knowledge, or (z)
suggested by or resulting from any work performed by Executive for the Group.

 

(b)    
For purposes of this Agreement, “Intellectual Property Rights” means any and all worldwide rights, title, or interest
existing now or in the future under patent law, trademark law, copyright law, industrial rights design law, moral rights law, trade secret
law, and any and all similar proprietary rights, however denominated, and any and all continuations, continuations-in-part, divisions,
renewals, reissue, reexaminations, extensions and/or restorations thereof, now or hereafter in force and effect, including without limitation
all patents, patent applications, industrial rights, mask works rights, trademarks, trademark applications, trade names, slogans, logos,
service marks and other marks, copyrightable material, copyrights, copyright applications, moral rights, trade secrets, and trade dress.

 

(c)    
Executive acknowledges and agrees that all Company Work Product is and shall belong to the Company. Executive shall and hereby does irrevocably
assign and transfer to the Company all of Executive’s right, title, and interest in and to all Company Work Product, which assignment
shall be effective as of the moment of creation of such Company Work Product without requiring any additional actions of the parties.

 

(d)    
All copyrightable material included in Company Work Product that qualifies as a “work made for hire” under the U.S. Copyright
Act is deemed a “work made for hire” created for and owned exclusively by the Company, and the Company shall be deemed the
owner of the copyright and all other Intellectual Property Rights associated therewith.

 

    5

     

    

 

(e)    
To the extent any of the rights, title, and interest in and to Company Work Product cannot be assigned by Executive to the Company, Executive
hereby grants to the Company a perpetual, exclusive, royalty-free, transferable, assignable, irrevocable, worldwide license (with rights
to sublicense through multiple tiers of sublicensees) to practice such non-assignable rights, title, and interest. To the extent any of
the rights, title, and interest in and to Company Work Product can neither be assigned nor licensed by Executive to the Company, Executive
hereby irrevocably waives and agrees never to assert such non-assignable and non-licensable rights, title, and interest against the Company
or its affiliates, or its and their directors, officers, agents, employees, contractors, successors, or assigns. For the avoidance of
doubt, this Section 7(e) shall not apply to any Work Product that (i) does not relate, at the time of creation, making, development,
discovery, derivation, conception, reduction to practice, authoring, or fixation in a tangible medium of expression of such Work Product,
to the Group’s business or actual or demonstrably anticipated research, development or business; and (ii) was developed entirely
in Executive’s own time; and (iii) was developed without use of any of the Group’s equipment, supplies, facilities, or trade
secret information; and (iv) did not result from any work Executive performed for the Group.

 

(f)     
Executive agrees, represents, and warrants that to the extent any Prior Work Product exists relating in any way to the Group’s existing
business, or demonstrably anticipated research and development or future business, which was created, made, developed, discovered, derived,
conceived, reduced to practice, authored, or fixed in a tangible medium of expression by Executive prior to Executive’s employment
with the Company (collectively, the “Prior Work Product”) the Executive shall notify the Company of such Prior Work
Product and obtain the Company’s prior written consent prior to using in any way the Prior Work Product during the course of the
Executive’s employment with the Company. Executive agrees, represents, and warrants that Executive has no rights in or to any Work
Product related to Executive’s employment with the Company, or to the Company and its affiliates generally, other than the Prior
Work Product. Executive hereby grants to the Company a perpetual, royalty-free, irrevocable, worldwide, fully paid-up license (with rights
to transfer, assign, and sublicense through multiple tiers of sublicensees) to practice all Intellectual Property Rights relating to any
Prior Work Product that Executive uses, incorporates, or permits to be incorporated, in any Company Work Product. Notwithstanding the
foregoing, Executive will not use, incorporate, or permit to be incorporated, any Prior Work Product in any Company Work Product without
the Company’s prior written consent.

 

(g)    
Executive agrees, during and after Executive’s employment, to perform and to assist the Company, its affiliates, and its and their
successors, assigns, delegates, nominees, and legal representatives with all acts that the Company deems necessary or desirable to permit
and assist the Company in applying for, obtaining, perfecting, protecting, and enforcing the full benefits, enjoyment, rights, and title
throughout the world of the Company in and to all Company Work Product, which acts and assistance may include, without limitation, the
signing and execution of documents (at no cost to the Company) and assistance or cooperation in the filing, prosecution, registration,
and memorialization of assignment of any applicable Intellectual Property Rights; acts pertaining to the enforcement of any applicable
Intellectual Property Rights; and acts pertaining to other legal proceedings related to Company Work Product. If the Company is unable
for any reason to secure Executive’s signature to any document that the Company deems necessary or desirable to permit and assist
the Company in applying for, obtaining, perfecting, protecting, and enforcing the full benefits, enjoyment, rights and title throughout
the world of the Company in and to all Company Work Product, Executive hereby irrevocably designates and appoints the Company, its officers,
and directors as Executive’s attorney in fact to sign and execute such documents in Executive’s name, all with the same legal
force and effect as if executed by Executive. This designation of power of attorney is a power coupled with an interest and is irrevocable.
Executive will not retain any proprietary interest in any Company Work Product and shall not register, file, seek to obtain, or obtain
any Intellectual Property Rights covering any Company Work Product in Executive’s own name.

 

(h)    
Executive agrees to disclose and describe to the Company promptly and in writing to the Company all Company Work Product to which the
Company is entitled as provided above. Executive shall deliver all Company Work Product in Executive’s possession whenever the Company
so requests, and, in any event, prior to or upon Executive’s termination of employment. After the Company confirms receipt of Company
Work Product, Executive shall delete or destroy all Company Work Product in Executive’s possession whenever the Company so requests
and at the Company’s reasonable direction, without retaining any copies thereof, and, in any event, prior to or upon Executive’s
termination of employment.

 

    6

     

    

 

(i)      
Consistent with Executive’s obligations under Section 6, Executive shall hold in the strictest confidence, and will not disclose,
furnish or make accessible to any person or entity (directly or indirectly) Company Work Product, except as required in accordance with
Executive’s duties as an Executive of the Company.

 

(j)     
Executive agrees to disclose promptly in writing to the Company all Work Product created, made, developed, discovered, derived, conceived,
reduced to practice, authored, or fixed in a tangible medium of expression by Executive for three (3) months after the termination of
Executive’s employment with the Company, whether or not Executive believes such Work Product is subject to this Agreement, to permit
a determination by the Company as to whether or not the Work Product is or should be the property of the Company. Executive recognizes
that Work Product or Confidential Information relating to Executive’s activities while working for the Company and created, made,
developed, discovered, derived, conceived, reduced to practice, authored, or fixed in a tangible medium of expression by Executive, alone
or with others, within three (3) months after termination of Executive’s employment with the Company, may have been so created,
made, developed, discovered, derived, conceived, reduced to practice, authored, or fixed in a tangible medium of expression by Executive
in significant part while employed by the Company. Accordingly, Executive agrees that such Work Product and Confidential Information shall
be presumed to have been created, made, developed, discovered, derived, conceived, reduced to practice, authored, or fixed in a tangible
medium of expression during Executive’s employment with the Company and are to be promptly disclosed and assigned to the Company
unless and until Executive establishes the contrary by written evidence satisfying a clear and convincing evidence standard of proof.

 

(k)          
For the avoidance of doubt, Executive shall not be entitled to any additional or special compensation or reimbursement in fulfilling Executive’s
obligations under this Section 7, except that the Company, in its sole discretion, may reimburse Executive for any reasonable expenses
which Executive may incur on behalf of the Company.

 

8.     Immunity
under Defend Trade Secrets Act of 2016.

 

The Defend Trade Secrets
Act of 2016 (the “Act”) provides that:  (1) An individual shall not be held criminally or civilly liable under any Federal
or State trade secret law for the disclosure of a trade secret that:  (A) is made – (i) in confidence to a Federal, State,
or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating
a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is
made under seal.  The Act further provides that:  an individual who files a lawsuit for retaliation by an employer for reporting
a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the
court proceeding, if the individual:  (A) files any document containing the trade secret under seal; and (B) does not disclose the
trade secret, except pursuant to court order.

 

9.     Non-Competition;
Non-Solicitation.

 

(a)       
Non-Competition. During the Employment Period and for a period of twelve (12) months thereafter (the “Restricted Period”),
Executive shall not, without the prior written consent of the Board, directly or indirectly, whether as owner, consultant, Executive,
partner, venturer, agent, through stock ownership, investment of capital, lending of money or property, rendering of services, or otherwise,
engage or participate in a Competitive Business operating within the Restricted Area.

 

    7

     

    

 

As used in this Agreement,
the term “Competitive Business” means any firm, company or business organization (including in each case any entity
which directly or indirectly controls, is controlled by, or is under common control by any firm, company or business organization) which,
controls, provides or owns any clinical program (excluding phase 1 clinical programs) utilizing a Competing Therapy or which is commercializing
or controlling (whether directly or indirectly) the commercialization of any Competing Therapy or which has filed for a marketing authorization
in relation to any Competing Therapy. As used in this Agreement, the term “Competing Therapy” means any cell therapy
that comprises the same type of active component or moiety (either alone or in combination with any other active component) as any cell
therapy owned, licensed or controlled by the Company (each a “Company Cell Therapy”) and where such Company Cell Therapy
has either been commercialized by the Company or any of its licensees within the 12 months preceding termination or expiry of the Employment
Period or has been the subject of any clinical program (excluding any phase 1 clinical program) sponsored or controlled by the Company
in the 12 months preceding termination or expiry of the Employment Period. By way of non-limiting example, the active component of a TCR
T-cell therapy would be the TCR (T-cell receptor). Notwithstanding the foregoing, (A) a cell therapy will not be a Competing Therapy where
it only targets or is approved for treatment of indications which are different from those in relation to which a Company Cell Therapy
has been approved for use, whether as part of a clinical trial or marketing authorization; and (B) Executive may own up to one percent
(1%) of the outstanding stock of a publicly held corporation which constitutes or is affiliated with a Competitive Business.

 

As used in this Agreement,
the term “Restricted Area” means the United States, the United Kingdom and any other country in which the Company or
any affiliated company; (i) at any time in the twelve (12) months preceding the termination of the Employment Period, has manufactured
for, marketed, sold and/or distributed products or services or conducted clinical trials involving the use of T-cell therapy to treat
or diagnose human disease; or (ii) plans to, during the Restricted Period, manufacture for, market, sell and/or distribute products or
services or conduct clinical trials involving the use of T-cell therapy to treat or diagnose human disease.

 

(b)    
Non-Solicitation of Employees. During the Employment Period and the Restricted Period, Executive shall not, directly or indirectly
(through another person, entity or otherwise): (i) solicit, induce or attempt to induce any Restricted Person of the Company or any affiliated
company to leave the employ of the Company or any affiliated company, or in any way interfere with the relationship between the Company
or any affiliated company and any employee thereof; or (ii) hire any Restricted Person who was employed by the Company or any affiliated
company at any time during the six (6) months prior to such person’s hiring by Executive.

 

In this Agreement, “Restricted
Person” means anyone employed or engaged either (i) directly by the Company or any affiliated company or (ii) indirectly by
the Company or any affiliated company through a contract research organization or contract manufacturing organization, at (i) the level
of line management (including associate director, director, vice president, senior vice president) or above or equivalent or (ii) research
and development staff, manufacturing staff or equivalent or (iii) key personnel engaged for the provision of services to the Company or
any affiliated company, and who was so employed or engaged in the six months prior to the termination of employment. The non-solicitation
provisions explicitly cover all forms of oral, written or electronic communication, including, but not limited to, communications by email,
regular mail, telephone, fax, instant message and social media platforms whether or not in existence at the date of this Agreement.

 

(c)    
Non-Solicitation of Others. During the Employment Period and the Restricted Period, Executive shall not, directly or indirectly
(through another person, entity or otherwise): (i) contact, solicit or accept the business of any customer, vendor or client of the Company
or affiliated company for any reason except for non-competing purposes unrelated to the use of T-cell therapy to treat or diagnose human
disease; or (ii) induce or seek to influence any customer, vendor or client of the Company or affiliated company to discontinue, modify
or reduce its business relationship with the Company or affiliated company for any reason.

 

(d)    
If, at the time of enforcement of Section 6, 7 or 9 of this Agreement, a court shall hold that the duration, scope or
geographical area restrictions stated herein are unreasonable under circumstances then existing, the parties hereto agree that the
maximum duration, scope or geographical area reasonable under such circumstances shall be substituted for the stated duration, scope
or area and that the court shall be allowed to revise the restrictions contained herein to cover the maximum period, scope and area
permitted by law.

 

    8

     

    

 

(e)    
Executive acknowledges that Executive’s compliance with Sections 6, 7 and 9 of this Agreement is necessary to protect the
goodwill, customer relations, trade secrets, confidential information and other proprietary and legitimate business interests of the Company.
Executive acknowledges that any breach of any of these covenants will result in irreparable and continuing damage to the Company’s
business for which there will be no adequate remedy at law and Executive agrees that, in the event of any such breach of the aforesaid
covenants, the Company and its successors and assigns shall be entitled to injunctive relief and to such other and further relief as may
be available at law or in equity. Accordingly, Executive expressly agrees that upon any breach, or threatened breach, of the terms of
this Agreement, the Company shall be entitled as a matter of right, in any court of competent jurisdiction in equity or otherwise to enforce
the specific performance of the Executive’s obligations under this Agreement, to obtain temporary and permanent injunctive relief
without the necessity of proving actual damage to the Company or the inadequacy of a legal remedy, and without posting bond. In the event
a court orders the Company to post a bond in order to obtain such injunctive relief for a claim under this Agreement, Executive agrees
that the Company will be required to post only a nominal bond. The rights conferred upon the Company in this Section shall not be exclusive
of any other rights or remedies that the Company may have at law, in equity or otherwise.

 

(f)     
In the event that Executive violates any of the covenants in this Agreement and the Company commences legal action for injunctive or other
relief, then the Company shall have the benefit of the full period of the covenants such that the covenants shall have the duration of
twelve (12) months computed from the date Executive ceased violation of the covenants, either by order of the court or otherwise. Executive
acknowledges that any claim or cause of action of Executive against the Company shall not constitute a defense to the enforcement by the
Company of the covenants of Executive in this Agreement. In the event the Company obtains any such injunction, order, decree or other
relief, in law or in equity, Executive shall be responsible for reimbursing the Company for all costs associated with obtaining the relief,
including reasonable attorneys’ fees and expenses and costs of suit.

 

(g)    
Executive acknowledges and agrees that the restrictive covenants contained herein (i) are necessary for the reasonable and proper protection
of the goodwill of the Company and its trade secrets, proprietary data and confidential information, (ii) are reasonable with respect
to length of time, scope and geographic area and (iii) will not prohibit Executive from engaging in other businesses or employment for
the purpose of earning a livelihood following the termination of Executive’s relationship with the Company.

 

10.     
Executive’s Representations and Covenants. Executive hereby represents and warrants to the Company that: (i) the execution,
delivery and performance of this Agreement by Executive do not and shall not conflict with, breach, violate or cause a default under any
contract, agreement, instrument, order, judgment or decree to which Executive is a party or by which Executive is bound; (ii) Executive
is not a party to or bound by any employment agreement, non-compete agreement or confidentiality agreement with any other person or entity;
(iii) upon the execution and delivery of this Agreement by the Company, this Agreement shall be the valid and binding obligation of Executive,
enforceable in accordance with its terms; and (iv) Executive is authorized to work in the United States without restriction. Executive
hereby acknowledges and represents that she has been made aware of her right to consult with independent legal counsel regarding her rights
and obligations under this Agreement and that she fully understands the terms and conditions contained herein. Executive further covenants
that she shall not make any statements, other than pursuant to the performance of her job duties and responsibilities, to the press or
other media in connection with the Company and/or any affiliated company at any time either during or after the Employment Period without
the prior consent of the Chief Executive Officer.

 

    9

     

    

 

11.      Debarment

 

(a)    
Executive hereby certifies to the Company that, as provided in Section 306(a) and Section 306(b) of the U.S. Federal Food, Drug and Cosmetic
Act (21 U.S.C. SS 335a(a) and 335a(b)) and/or under any equivalent law within or outside the United States, Executive has not in the past
been and/or is not currently (or threatened to be or subject to any pending action, suit, claim investigation or administrative proceeding
which could result in Executive being) (i) debarred or (ii) excluded from participation in any federally funded healthcare program or
(iii) otherwise subject to any governmental sanction in any jurisdiction (including disqualification from participation in clinical research)
that would affect or has affected Executive's ability to perform Executive’s obligations under this Agreement, or Executive’s
employment with the Company or prevent Executive from working for the Company in any capacity in any jurisdiction.

 

(b)    
Executive hereby confirms that Executive is not on any of the following exclusion lists: (a) Food and Drug Administration Debarment List;
(b) General Services Administration Excluded Parties List System; or (c) Office of Inspector General List of Excluded Individuals/Entities.
Executive warrants and represents to the Company that Executive will notify the Company immediately if any of the foregoing occurs or
is threatened and that the obligation to provide such notice will remain in effect following the termination of Executive’s employment
with the Company for any reason, voluntary or involuntary. Any violation of this section by Executive may result in the withdrawal of
the offer of engagement or the termination of Executive’s employment with the Company. Immediately upon the request of the Company
at any time, Executive will certify to the Company in writing Executive’s compliance with the provisions of this section. Executive
hereby confirms that Executive understands that the Company will verify the information Executive
certifies under this Agreement. Falsified or incorrect information provided by Executive may result in the withdrawal of the offer of
engagement or the termination of Executive’s employment with the Company. 

 

12. Survival. Sections
5 through 23, inclusive, shall survive and continue in full force in accordance with their terms notwithstanding the termination of
the Employment Period.

 

13. Notices. Any notice
provided for in this Agreement shall be in writing and shall be either personally delivered, sent by reputable overnight courier service
or mailed by first class mail, return receipt requested, to the recipient at the address below indicated:

 

Notices to
Executive:

Cintia Piccina

at such address as most currently appears
in the records of the Company

 

Notices to
the Company:

Adaptimmune,
LLC

351 Rouse Boulevard

The Navy Yard

Philadelphia

PA 19112

Attention: Chief
Executive Officer

 

or such other address or to the attention of such
other person as the recipient party shall have specified by prior written notice to the sending party. Any notice under this Agreement
shall be deemed to have been given when so delivered, sent or mailed.

 

14. Severability.
Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or
rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement or any
action in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid,
illegal or unenforceable provision had never been contained herein.

 

15. Complete Agreement.
This Agreement, those documents expressly referred to herein and other documents of even date herewith embody the complete agreement and
understanding among the parties and supersede and preempt any prior understandings, agreements or representations by or among the parties,
written or oral, which may have related to the subject matter hereof in any way.

 

    10

     

    

 

16. No Strict Construction.
The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and
no rule of strict construction shall be applied against any party.

 

17. Counterparts.
This Agreement may be executed in separate counterparts (including by means of telecopied signature pages or electronic transmission in
portable document format (pdf)), each of which is deemed to be an original and all of which taken together constitute one and the same
agreement.

 

18. Successors and Assigns.
This Agreement, including, but not limited to, the terms and conditions
in Sections 6, 7 and 9, shall inure to the benefit of, and be binding upon, the heirs, executors, administrators, successors and
assigns of the respective parties hereto, but in no event may Executive assign or delegate to any other party Executive’s rights,
duties or obligations under this Agreement. Executive further hereby consents and agrees that the Company may assign this Agreement (including,
but not limited to, Sections 6, 7 and 9) and any of the rights or obligations hereunder to any third party in connection with the
sale, merger, consolidation, reorganization, liquidation or transfer, in whole or in part, of the Company’s control and/or ownership
of its assets or business. In such event, Executive agrees to continue to be bound by the terms of this Agreement.

 

19. Choice of Law.
All issues and questions concerning the construction, validity, enforcement and interpretation of this Agreement and the exhibits and
schedules hereto shall be governed by, and construed in accordance with, the laws of the Commonwealth of Pennsylvania, without giving
effect to any choice of law or conflict of law rules or provisions (whether of the Commonwealth of Pennsylvania or any other jurisdiction)
that would cause the application of the laws of any jurisdiction other than the Commonwealth of Pennsylvania.

 

20. Amendment and Waiver.
The provisions of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course
of conduct or course of dealing or failure or delay by any party hereto in enforcing or exercising any of the provisions of this Agreement
(including, without limitation, the Company’s right to terminate the Employment Period with or without Cause) shall affect the validity,
binding effect or enforceability of this Agreement or be deemed to be an implied waiver of any provision of this Agreement.

 

21. Insurance. The
Company may, at its discretion, apply for and procure in its own name and for its own benefit life and/or disability insurance on Executive
in any amount or amounts considered advisable. Executive agrees to cooperate in any medical or other examination, supply any information
and execute and deliver any applications or other instruments in writing as may be reasonably necessary to obtain and constitute such
insurance.

 

22. Agreement to Arbitrate.

 

(a)  
Notwithstanding any express provision to the contrary, Executive and the Company agree that any claim, controversy or dispute
between Executive and the Company (including without limitation the Company’s affiliates, officers, executives,
representatives, or agents) arising out of or relating to this Agreement, the employment of Executive, the cessation of employment
of Executive, or any matter relating to the foregoing shall be submitted to and settled by arbitration before a single arbitrator in
a forum of the American Arbitration Association (“AAA”) located in Philadelphia, Pennsylvania, and conducted in
accordance with the National Rules for the Resolution of Employment Disputes. In such arbitration: (i) the arbitrator shall agree to
treat as confidential evidence and other information presented by the parties to the same extent as Confidential Information under
this Agreement must be held confidential by Executive; (ii) the arbitrator shall have no authority to amend or modify any of the
terms of this Agreement; and (iii) the arbitrator shall have ten (10) business days from the closing statements or submission of
post-hearing briefs by the parties to render his/her decision.

 

(b)    All
AAA-imposed costs of said arbitration, including the arbitrator’s fees, if any, shall be borne by the Company. All legal fees incurred
by the parties in connection with such arbitration shall be borne by the party who incurs them, unless applicable statutory authority
provides for the award of attorneys’ fees to the prevailing party and the arbitrator’s decision and award provides for the
award of such fees.

 

    11

     

    

 

(c)    Any
arbitration award shall be final and binding upon the parties, and any court having jurisdiction may enter a judgment on the award. The
foregoing requirement to arbitrate claims, controversies, and disputes applies to all claims or demands by Executive, including without
limitation, any rights or claims Executive may have under the Age Discrimination in Employment Act of 1967, Title VII of the Civil Rights
Act of 1964, the Americans with Disabilities Act of 1991, the Equal Pay Act, the Family and Medical Leave Act or any other federal, state
or local laws or regulations pertaining to Executive’s employment or the termination of Executive’s employment.

 

(d)    All claims
must be arbitrated, with the limited exception of claims for violations of Sections 6, 7 or 9 of this Agreement. In the event of
an alleged breach of Sections 6, 7 or 9 of this Agreement by Executive, the Company has the option to elect between arbitration
and a judicial forum.

 

23. Corporate Opportunity.
During the Employment Period, Executive shall submit to the Company all business, commercial and investment opportunities or offers presented
to Executive or of which Executive becomes aware (including in Executive’s capacity as agent, employee, director or officer of the
Company), irrespective of Executive’s evaluation of the reasonableness or desirability of the Company’s investigation thereof,
which relate to the business of the Company or any of its affiliates or subsidiaries (the “Business”) at any time during
the Employment Period (“Corporate Opportunities”). Executive acknowledges that all such Corporate Opportunities are
for the benefit of the Company and that Executive would be in breach of Executive’s duties to the Company if Executive accepted
or pursued, directly or indirectly, any such Corporate Opportunity on Executive’s own behalf.

 

As used in this Agreement,
the term “Business” means the business of developing, designing, testing, marketing, selling, distributing or manufacturing
products or services involving the use of T cell therapy to treat or diagnose human disease and/or any further business that may be developed
by the Company or any of its affiliates of which Executive is aware.

 

24. Executive’s
Cooperation. During the Employment Period and thereafter, Executive shall reasonably cooperate with the Company and its affiliates
or subsidiaries in any internal investigation or administrative, regulatory or judicial proceeding as reasonably requested by the Company
(including, without limitation, Executive’s being reasonably available to the Company upon reasonable notice for interviews and
factual investigations, appearing at the Company’s reasonable request to give testimony without requiring service of a subpoena
or other legal process, volunteering to the Company all pertinent information and turning over to the Company all relevant documents which
are or may come into Executive’s possession, all at times and on schedules that are reasonably consistent with Executive’s
other permitted activities and commitments) at reasonable times. In the event the Company requires Executive’s cooperation in accordance
with this Section 24, the Company shall reimburse Executive solely for reasonable travel expenses (including lodging and meals,
upon submission of receipts). Nothing about the foregoing shall preclude Executive from testifying truthfully in any forum or from providing
truthful information to any government agency or commission.

 

25. 409A Compliance.

 

(a)          
The intent of the parties is that payments and benefits under this Agreement comply with Section 409A and, accordingly, to the maximum
extent permitted, this Agreement shall be interpreted to be in compliance therewith. In no event shall the Company or its subsidiaries
or affiliates be liable for any additional tax, interest or penalty that may be imposed on Executive under Section 409A or damages
for failing to comply with Section 409A.

 

(b)          
A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment
of any amounts or benefits upon or following a termination of employment unless such termination is also a “separation from service”
within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a “termination,”
 “termination of employment” or like terms shall mean “separation from service.”

 

    12

     

    

 

(c)          
To the extent that reimbursements or other in-kind benefits under this Agreement constitute “nonqualified deferred compensation”
for purposes of Section 409A: (i) all such expenses or other reimbursements hereunder shall be made on or prior to the last
day of the taxable year following the taxable year in which such expenses were incurred by Executive; (ii) any such right to reimbursement
or in-kind benefits shall not be subject to liquidation or exchange for another benefit; and (iii) no such reimbursement, expenses
eligible for reimbursement, or in-kind benefits provided in any taxable year shall in any way affect the expenses eligible for reimbursement,
or in-kind benefits to be provided, in any other taxable year.

 

(d)          
For purposes of Section 409A, Executive’s right to receive any installment payments pursuant to this Agreement shall be treated
as a right to receive a series of separate and distinct payments.

 

(e)          
Notwithstanding any other provision of this Agreement to the contrary, in no event shall any payment under this Agreement that constitutes
 “nonqualified deferred compensation” for purposes of Section 409A be subject to offset by any other amount unless otherwise
permitted by Section 409A.

 

    13

     

    

 

IN WITNESS WHEREOF,
the parties hereto have executed this Employment Agreement as of the date first written above.

 

	 	ADAPTIMMUNE, LLC
	 	 	 
	 	By:	/s/ Helen Tayton-Martin
	                  	 	 
	 	Name: 	Helen Tayton-Martin 
	 	 	 
	 	Position: 	President and Secretary 
	 	 	 
	 	/s/ Cintia Piccina
	 	Cintia Piccina

 

    14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]